Posted November 20, 2020
Pharmaceutical company Pfizer, Inc. announced on Nov. 9, 2020 that ongoing Phase 3 clinical trial of its COVID-19 mRNA vaccine candidate suggests the vaccine may be 90 percent effective in preventing infection with the SARS-CoV-2 virus. The news sent Pfizer’s stock price surging to a high of $41.99 per share and earned CEO Albert Bourla $5.6 million when he sold 60 percent of his holdings (132,508 shares) at $41.94 per share on the same day.  Read more.